Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Johnson & Johnson reported higher-than-expected fourth-quarter revenues, driven by strong cancer drug sales, amidst its ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

Johnson & Johnson MedTech’s Dual Energy THERMOCOOL SMARTTOUCH SF Catheter has gained the European CE mark approval for ...

Analysts expect a profit per share of $2.02, which is a decline of 11.8% from the prior year period. The consensus revenue ...